Stemson Therapeutics announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board.
Read More »Stemson Therapeutics announced today the addition of Kapil Bharti, Ph.D. and George Murphy, M.D. to its Scientific Advisory Board. The addition of these distinguished leaders in the field significantly bolster Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles. Dr. Bharti is a Senior Investigator at the National Eye Institute at the National Institutes of Health and is a world renowned expert in regenerative medicine,
Read More »Stemson Therapeutics has been chosen as Select Technology Contributor at the 2021 Global Hair Loss Summit (GHLS). GHLS is the premier virtual educational and networking event in the field of surgical hair restoration and all associated modalities. Founder and CEO Geoff Hamilton has been given the honor to present a keynote address entitled “Developing Induced Pluripotent Stem Cell Technology to Engineer a De Novo Supply of Hair Follicles to Treat Hair Loss.”’ Mr.
Read More »Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles.
Read More »
It’s estimated over 60 million people in the US are losing their hair. At least 20% of them are under the age of 30, and more than 30% of women will experience noticeable hair loss.
Its root causes are diverse, from autoimmune conditions, to long-lasting chemotherapy effects, to scarring and injuries, to genetics and age-related conditions.
Regardless of the cause, for most people, losing their hair hits them very hard emotionally.
Read More »Biotech innovator Stemson are scoping out research and development investments in the UK to develop a revolutionary cure for baldness in partnership with London-based Fortunis Capital as their lead investor in the country, it was announced today.
San Diego-based Stemson Therapeutics is developing technology to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
Funding from impact investor Fortunis will support research and development of the product solution and position the UK as a leading contender to conduct human clinical trials,
Read More »Stemson Therapeutics announced today a $7.5 million seed financing led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital to advance development of Stemson’s therapeutic solution to cure hair loss. Stemson aims to restore human hair growth with a novel approach using the patient’s own cells to generate new hair follicles.
Read More »Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.
Read More »Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development. Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.
“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team. Her expertise in tissue engineering strategies,
Read More »Stemson Therapeutics is pleased to announce Cenk Sumen, PhD, will join our team as Chief Technology Officer. Dr. Sumen will lead Stemson’s manufacturing efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy. He will join Stemson’s executive team, reporting to Geoff Hamilton, Chief Executive Officer of Stemson, and will serve on the company Board of Directors.
“Cenk brings almost a decade of experience translating early stage cell therapy candidates into GMP compliant manufacturing environments.
Read More »